

Article

Not peer-reviewed version

Substituent-Controllable Cascade Regioselective Annulation of β-Enaminones with N-Sulfonyl Triazoles for Modular Access to Imidazoles and Pyrroles

Hua Wang, Tongtong Zhou, Mengdi Wu, Qingqing Ye, Xinwei He

Posted Date: 15 May 2023

doi: 10.20944/preprints202305.0986.v1

Keywords: annulation; β -enaminones; imidazoles; pyrroles; N-sulfonyl trizaoles



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Substituent-Controllable Cascade Regioselective Annulation of β -Enaminones with N-Sulfonyl Triazoles for Modular Access to Imidazoles and Pyrroles

Hua Wang 1, Tongtong Zhou 1, Mengdi Wu 1, Qingqing Ye 2,* and Xinwei He 1,*

- Key Laboratory of Functional Molecular Solids, Ministry of Education, Anhui Laboratory of Molecula-Based Materials (State Key Laboratory Cultivation Base), College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241000, P.R. China
- ² Department of Medicine, Chuzhou City Vocation College, Chuzhou 239000, P.R. China
- * Correspondence: yeqingqing1983@sohu.com; xinweihe@mail.ahnu.edu.cn

Abstract: A controllable synthesis of trisubstituted imidazoles and pyrroles has been developed through rhodium(II)-catalyzed regioselective annulation of N-sulfonyl-1,2,3-trizaoles with β -enaminones. The imidazole ring was formed through 1,1-insertion of N-H bond to α -imino rhodium carbene and subsequential intramolecular 1,4-conjugate addition when α -carbon atom of amino group bearing with methyl, whereas utilizing phenyl substituent constructed pyrrole ring via intramolecular nucleophilic addition. Features such as mild conditions, good functional groups tolerance, gram-scale synthesis, and valuable transformations of the products qualified this unique protocol as an efficient tool for the synthesis of N-heterocycles.

Keywords: annulation; β-enaminones; imidazoles; pyrroles; N-sulfonyl trizaoles

1. Introduction

Nitrogen-containing heterocycles are privileged structural motifs in various of natural products and bioactive compounds.[1,2] Among them, imidazole and pyrrole framework are very common structural units widely distributed in natural products, pharmaceutics, agrochemicals, and other functional materials.[3,4] For this reason, the synthesis of such compounds continues to be a hot topic in modern synthetic chemistry.[5–8] Consequently, a large number of new reactions have been developed to construct structurally diverse imidazole and pyrrole derivatives, such as multicomponent reactions,[9,10] [3+2] cycloaddition,[11–14] as well as both metal-catalyzed inter-[15,16] and intramolecular[17,18] cyclization strategies. Despite all the achievements, the development of efficient methods for their synthesis, particularly regiocontrolled synthesis of those containing multiple substituents, from readily accessible compounds is of ever-increasing importance.

In the past decades, 1,2,3-triazoles have emerged as capable precursors for the synthesis of various nitrogen heterocycles.[19,20] Upon treatment with rhodium(II) catalysts, N-sulfonyl-1,2,3-triazoles readily undergo denitrogenative reaction to form α -imino rhodium carbenes, a versatile intermediate that could promote a wide range of transformations.[21,22] Besides the common reactivity, such as cyclopropanation,[23,24] X-H insertion,[25–28] and ylide formation,[29–31] α -imino rhodium carbenes can be employed as [1C]- or aza-[3C]-synthons to participate in stepwise cycloadditions, giving various N-heterocycles.[32–35] As the major part of our research efforts in developing new methodologies for the construction of heterocycles,[36–39] we herein describe an efficient strategy for regioselective synthesis of trisubstituted imidazoles and pyrroles involving the cascade N-H insertion to α -imino rhodium carbene followed by substituent-controllable intramolecular annulation (Scheme 1), in which the α -imino rhodium carbene acted as a [2C] and aza-[3C]-synthons, respectively.

N=N
$$R^1$$
 R^1 R^2 R^2

Scheme 1. Substituent-controllable cascade strategy for the synthesis of trisubstituted imidazoles and pyrroles.

2. Results and Discussion

The optimization of a one-pot procedure for the formation of imidazole 3a from triazole 1a and β -enaminone 2a was undertaken (Table 1). Screening of various transition-metal catalysts revealed that dirhodium catalyst Rh₂(OAc)₄ and Rh₂(oct)₄ were demonstrated more efficient than other metal catalysts for this reaction (Table 1, entries 1-6). Further investigation showed that at a lower catalytic loading (2 mol%) had a positive effect on the reaction (Table 1, entries 7-10). Other solvents, including toluene and chlorobenzene, could better promote this transformation and then utilization chlorobenzene for further optimization (Table 1, entries 11-16). Further variation of reaction temperatures revealed that 80 °C was the optimal condition (Table 1, entries 17-19). Extension of reaction time did not find beneficial to the product yield (Table 1, entries 20-22). Thus, the optimal reaction conditions were found to be Rh₂(oct)₄ in chlorobenzene at 90 °C for 12 h (Table 1, entry 13).

Table 1. Optimization of the reaction conditions a.

		Ja	
Entry	Catalyst (x mol%)	Solvent	Yield (%) ^b
1	Rh ₂ (OAc) ₄ (4)	DCM	56
2	Rh2(oct)4 (4)	DCM	58
3	CuI (4)	DCM	44
4	Sc(OTf)3 (4)	DCM	trace
5	Co ₂ (CO) ₈ (4)	DCM	nr
6	Ni(acac) ₂ (4)	DCM	nr
7	Rh ₂ (oct) ₄ (3)	DCM	73
8	Rh ₂ (oct) ₄ (2)	DCM	79
9	Rh ₂ (oct) ₄ (1)	DCM	41
10	/	DCM	nr
11	Rh ₂ (oct) ₄ (2)	DCE	55
12	Rh ₂ (oct) ₄ (2)	toluene	84
13	Rh ₂ (oct) ₄ (2)	PhCl	96
14	Rh ₂ (oct) ₄ (2)	CH ₃ OH	trace
15	Rh ₂ (oct) ₄ (2)	CH_3NO_2	trace
16	Rh ₂ (oct) ₄ (2)	DMF	nr
17^{c}	Rh ₂ (oct) ₄ (2)	PhCl	nr

18^d	Rh ₂ (oct) ₄ (2)	PhCl	87
19^e	Rh ₂ (oct) ₄ (2)	PhCl	94
20 ^f	Rh ₂ (oct) ₄ (2)	PhCl	56
218	Rh ₂ (oct) ₄ (2)	PhCl	78
22^{h}	Rh ₂ (oct) ₄ (2)	PhCl	96

^aReaction conditions: 4-phenyl-1-tosyl-1*H*-1,2,3-triazole **1a** (0.2 mmol), 3-amino-1-phenylbut-2-en-1-one **2a** (0.2 mmol), and catalyst in solvent (2 mL) at 90 °C for 12 h under argon atmosphere. ^b Isolated yields. ^c At 60 °C. ^d At 80 °C. ^e At 100 °C. ^f For 2 h. ^g For 6 h. ^h For 18 h. nr = no reaction.

With the optimal conditions in hand, we set out to explore the scope and generality of this [3+2] annulation with a combination of various substituted N-sulfonyl-1,2,3-triazoles 1 and β -enamino ketones 2 (Scheme 2). We firstly evaluated the effect of substituents of R1 group on the phenyl of N-sulfonyl-1,2,3-triazoles, and the results indicated that the introduction of electron-neutral (-Me, -Et), electron-rich (-OMe), and electron-deficient (-F, -Cl, -Br) substituents at the para-positions were tolerated to this transformation and gave the desired imidazoles (products 3b-3g) in 91-96% yields. Notably, the triazoles 1 bearing a bulky *tert*-butyl or a strong electron-withdrawing trifluoromethyl at the para-position of benzene ring led to a smooth reaction process, generating the corresponding products **3h** and **3i** in 93% and 75% yields, respectively. Moreover, the extended π structure did not show an influence, and the desired product 3j was successfully obtained in 80% yield. Additionally, substituents variations on the *meta*- and *ortho*-position could work well to produce the corresponding products **3k-3n** in 79-95% yields. Furthermore, the N-arylsulfonyl groups of the triazole substrates were also examined. The reactions of fluoro- and bromo-substituted phenylsulfonyl triazoles proceeded well, giving the desired products 3o and 3p in 91% and 76% yields, respectively. In addition, (Z)-3-amino-1-phenylpent-2-en-1-one was also viable substrate for the transformation, generating the product 3q in 56% yield.

Scheme 2. Substrate scope of *N*-sulfonyl-1,2,3-triazoles and *β*-enaminones for the synthesis of trisubstituted imidazoles. Reaction conditions: *N*-sulfonyl-1,2,3-triazoles **1** (0.2 mmol), *β*-enaminones **2** (0.2 mmol), and Rh₂(oct)₄ (2 mol%) in PhCl (2 mL) at 90 $^{\circ}$ C for 12 h under argon atmosphere. Isolated yields were reported.

Subsequently, an unexpected pyrrole product 5a was obtained in 91% yield under the standard conditions when the phenyl group (4a) replace of methyl group of β -enaminones. We further evaluated the feasibility by using the 2,5-diaryl β -enaminones as starting materials (Scheme 3). As

expected, a wide range of electronically different substituents, including alkyl, methoxy, halogen, and bulky *tert*-butyl groups, were successfully installed into the products **5a-5h**. Also, an extended π -system was implemented on the pyrrole structure (product **5i**). Particularly noteworthy is that the halogen groups (e.g. -F, -Cl, -Br) remained intact during the course of the reaction, which makes this transformation particularly attractive in terms of increasing the molecular complexity via transition metal-catalyzed coupling reactions (**5e-5g** and **5k-5m**). Additionally, we turned our attention to investigating the suitability of the substrate 1,3-diaryl β -enaminones **4**, and the desired products **5n-5q** were successfully obtained in 76-92% yields. It was gratifying that the introduction of a naphthyl and thienyl group also proceeded smoothly to produce the desired products **5o** and **5p** in a yield of 92% and 90%, respectively. Likewise, changing the phenyl group to a bulky isopropyl was also tolerated in the reaction to give the desired product **5r** in 86% yield.

Scheme 3. Substrate scope of *N*-sulfonyl-1,2,3-triazoles and β -enaminones for the synthesis of trisubstituted pyrroles. Reaction conditions: *N*-sulfonyl-1,2,3-triazoles **1** (0.2 mmol), β -enaminones **2** (0.2 mmol), and Rh₂(oct)₄ (2 mol%) in PhCl (2 mL) at 90 °C for 12 h under argon atmosphere. Isolated yields were reported.

Based on the above results, we hypothesis that the reaction of N-sulfonyl-1,2,3-triazoles and β -enaminones might be controlled by the steric hinder of the substituent on the α -position of amino. When a moderate steric group, such as n-propyl and n-butyl, was subjected to the amino α -position of β -enaminones under the standard conditions, the corresponding products imidazoles ($3\mathbf{r}$ and $3\mathbf{s}$) and pyrroles ($5\mathbf{s}$ and $5\mathbf{t}$) were obtained (Scheme $4\mathbf{a}$). In the synthesis of pyrroles, the presence of a methyl p-tolyl on the amino group resulted in a satisfactory yield of compounds $7\mathbf{a}$ and $7\mathbf{b}$ (72% and 85%), respectively (Scheme $4\mathbf{b}$).

Scheme 4. Further studies.

Notably, the reaction could be easily scaled up. As shown in Scheme 3, imidazole **3a** could be obtained in a satisfactory yield of 77% (1.44 g) when the scale of the reaction was increased to 5 mmol, and the 3,5-disubstituted pyrrole **5a** was obtained in an 75% yield (1.21 g) on the same scale. Subsequently, several transformations were performed to demonstrate the utility of the target products. The desulfonation of imidazole **3a** afforded the unprotected imidazole **8** in 96% yield (Scheme 5a). In addition, treating pyrrole **5a** with hydroxylamine hydrochloride and iodomethane successfully realized the formation of the pyrrolyl oxime **9** in 94% yield (Scheme 5b). In the presence of sodium hydride, *N*-methylation between compound **5a** and iodomethane easily generated *N*-methylpyrrole derivative **10** in 95% yield (Scheme 5c), highlighting the synthetic utility of the current protocol.

Scheme 5. Gram-scale synthesis and further synthetic transformations.

The mechanism of this reaction was proposed as shown in Scheme 4 on the basis of the above experimental results and previous reports.[40–42] α -Diazo imino intermediate **A**, which was generated from the ring-chain tautomerization of triazole **1a**, could be decomposed by the rhodium(II) catalyst efficiently to form α -imino rhodium carbene intermediate **B** along with the release of nitrogen gas. β -Enaminones (**2a** or **4a**) attacked the electrophilic carbene center of intermediate **B**, and 1,1-insertion occurred to convert intermediate **D** with the regeneration of the rhodium(II) catalyst. When R was methyl group, an imino-enamine taumerization could be induced to give more stable intermediate **E**, which could undergo an intramolecular 1,4-conjugate addition affording the intermediate **F**. The elimination of the intermediate **F** results the desired product **3a**. In the case of **4a**, the phenyl group was bulky to form the intermediate **D**'. Therefore, after the subsequential intramolecular nucleophilic addition and elimination process, the corresponding product **5a** was obtained.

Scheme 4. Proposed mechanism for the formation of NH-free isoquinolones.

3. Materials and Methods

The detailed procedures for the synthesis and characterization of the products are given in Appendix A section.

4. Conclusions

In conclusion, we have demonstrated that the Rh(II)-catalyzed substituent-controllable regioselective annulations provide a new synthetic strategy to trisubstituted imidazoles and pyrroles. The highlight of the current reaction is the substituent-dependent product selectivity. The imidazole skeleton was formed via N-H insertion to α -imino rhodium carbene, followed by intramolecular 1,4-conjugate addition when α -carbon atom of amino group bearing with methyl. Switching methyl to phenyl group, the pyrrole framework was generated through N-H insertion and intramolecular nucleophilic addition process. The large-scale reactions and transformations of the products further demonstrated the potential synthetic value of this strategy.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Characterization data for product 3 and 4, include ¹H- and ¹³C-NMR spectroscopies are available online. CCDC 2260879 and 2260880 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033.

Author Contributions: Conceptualization, X.H., Q.Y.; methodology, H.W. and T.Z.; formal analysis, T.Z.; data curation, H.W.; writing—original draft preparation, H.W. and Y.Q.; writing—review and editing, X.H. and Q.Y.; supervision, Q.Y. and X.H.; project administration, X.H. All authors have read and agreed to the published version of the manuscript.

Funding: We thank the Natural Scientific Research Foundations of Anhui Provincial Universities (2022AH050210), the Excellent Scientific Research and Innovation Team of Anhui Provincial Universities (No. 2022AH010011), the University Synergy Innovation Program of Anhui Province (No. GXXT-2020-074), and the Excellent Young Talents Support Program of Education Administration of Anhui Province (No. gxyq2022233) for financial support.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in this article.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the authors.

Appendix A. Experimental Section

Unless otherwise specified, all reagents and starting materials were purchased from commercial sources and used as received, and the solvents were purified and dried using standard procedures. The chromatography solvents were technical grade and distilled prior to use. The NMR spectra were recorded with a Bruker Avance 500 spectrometer (500 MHz for 1 H and 125 MHz for 13 C) with CDCl₃ as solvent with tetramethylsilane (TMS) as the internal standard at room temperature. Chemical shifts are given in δ relative to TMS, the coupling constants J are given in Hz. HRMS spectra were obtained with an Agilent 6200 using a quadrupole time-of-flight mass spectrometer equipped with an ESI source. The melting points were measured using SGWX-4 melting point apparatus and not corrected. The X-ray source used for the single crystal X-ray diffraction analysis of compound 3a and 5a was Mo K α (λ = 0.71073 Å), and the thermal ellipsoid was drawn at the 30% probability level.

General procedure for the synthesis of trisubstituted imidazoles 3 and pyrroles 5. N-Sulfonyl-1H-1,2,3-triazoles 1 (0.2 mmol), β -enaminones 2 (0.2 mmol), and Rh₂(oct)₄ (2 mol%) were successively added to a Schlenk reaction tube. The reaction set was evacuated and backfilled with argon atmosphere for three times. Then chlorobenzene (2.0 mL) was added into the reaction tube through a syringe. The reaction mixture was stirred vigorously in an oil bath preheated to 90 °C for 12 hours. After the reaction was complete, the reaction mixture was cooled to room temperature, extracted with CH₂Cl₂ (3 × 10 mL), and washed with brine. The organic layers were combined, dried over Na₂SO₄ and then evaporated under vacuum. The residue was purified by flash column chromatography on silica gel (200-300 mesh) using ethyl acetate and petroleum ether (1:8, v/v) as the elution solvent to give desired products 3 or 5.

General procedure for the synthesis of compound 8. 2-Methyl-4-phenyl-1-tosyl-1*H*-imidazole 3a (0.15 mmol) and NaOH (2.25 mmol) were successively added to a Schlenk reaction tube. The reaction set was evacuated and backfilled with argon atmosphere for three times. Then methanol (2.0 mL) was added into the reaction tube through a syringe. The reaction mixture was stirred vigorously in an oil bath preheated to 70 °C for 30 minutes. After the reaction was complete, the reaction mixture was cooled to room temperature, extracted with CH₂Cl₂ (3 × 10 mL), and washed with brine. The organic layers were combined, dried over Na₂SO₄ and then evaporated under vacuum. The residue was purified by flash column chromatography on silica gel (200-300 mesh) using ethyl acetate and petroleum ether (1:3, v/v) as the elution solvent to give desired product 8 in 96% yield.

General procedure for the synthesis of compound 9. A mixture of (2,5-diphenyl-1*H*-pyrrol-3-yl)(phenyl)methanone 5a (0.2 mmol), hydroxylamine hydrochloride (0.4 mmol), and sodium acetate (0.5 mmol) were added to a round-bottomed flask with reflux condenser. Ethanol (4 mL) was then added and the reaction mixture was stirred vigorously at reflux in oil bath with stirring 12 hours. After quenching with water, the residue was extracted with ethyl acetate twice. The combined layer was washed with brine, dried over Na₂SO₄ and then evaporated under vacuum. The residue was purified by flash column chromatography on silica gel (200-300 mesh) using ethyl acetate and petroleum ether (1:8, v/v) as the elution solvent to give desired product 9 in 94% yield.

General procedure for the synthesis of compound 10. NaH (60% in mineral oil, 0.5 mmol, 1.7 equiv.) was added to a solution of the 5a (0.25 mmol) in DCM (4 mL) at 0 °C in portions. After stirring for 5 min at 0 °C, MeI (0.22 mmol, 1.1 equiv.) was added drop-wise and the reaction mixture was allowed to warm to room temperature and stirred for another 19 h. After quenching with water, the residue was extracted with ethyl acetate twice. The combined organic layer was washed with brine, dried over Na₂SO₄, filtrated and concentrated, and purified by column chromatography to afford 10 in 95% yield.

7

2-Methyl-4-phenyl-1-tosyl-1H-imidazole (3a). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 96% yield (60 mg); mp 122-124 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 7.0 Hz, 2H), 7.67 (s, 1H), 7.39-7.35 (m, 4H), 7.25 (d, J = 7.5 Hz, 1H), 2.57 (s, 3H), 2.44 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.5, 146.4, 141.0, 135.5, 132.7, 130.8, 129.1, 128.2, 127.8, 125.6, 114.4, 22.1, 15.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹7H¹7N²O²S 313.1005; Found 313.1006.

2-Methyl-4-(p-tolyl)-1-tosyl-1H-imidazole (3b). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 96% yield (62 mg); mp 60-62 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.80 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.0 Hz, 3H), 7.35 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 2.57 (s, 3H), 2.44 (s, 3H), 2.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.4, 146.3, 141.0, 138.0, 135.4, 130.7, 129.9, 129.8, 127.7, 125.5, 113.9, 22.1, 21.7, 15.6; HRMS (ESITOF) m/z: [M + H]+ Calcd for C¹8H¹9N²O²S 327.1162; Found 327.1170.

4-(4-Ethylphenyl)-2-methyl-1-tosyl-1H-imidazole (3c). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 95% yield (64 mg); mp 77-79 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.80 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.0 Hz, 3H), 7.34 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 2.64 (q, J = 7.5 Hz, 2H), 2.57 (s, 3H), 2.42 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.4, 146.3, 144.4, 141.0, 135.4, 130.8, 130.1, 128.6, 127.7, 125.5, 113.9, 29.1, 22.1, 15.9, 15.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹9H₂¹N₂O₂S 341.1318; Found 341.1319.

4-(4-Methoxyphenyl)-2-methyl-1-tosyl-1H-imidazole (3d). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 91% yield (62 mg); mp 66-68 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.80 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 9.0 Hz, 2H), 7.57 (s, 1H), 7.34 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 3.81 (s, 3H), 2.56 (s, 3H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 159.8, 146.4, 146.3, 140.8, 135.4, 130.7, 127.7, 126.9, 125.5, 114.5, 113.2, 55.7, 22.1, 15.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₁₈H₁₉N₂O₃S 343.1111; Found 343.1112.

4-(4-Fluorophenyl)-2-methyl-1-tosyl-1H-imidazole (3e). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 94% yield (62 mg); mp 107-109 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, J = 8.5 Hz, 2H), 7.69 (dd, J = 8.5, 5.0 Hz, 2H), 7.61 (s, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.06 (t, J = 8.5 Hz, 2H), 2.56 (s, 3H), 2.44 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 162.9 (d, J_{C-F} = 246.3 Hz), 146.6, 146.5, 140.1, 135.3, 130.8, 129.0, 127.8, 127.3 (d, J_{C-F} = 8.0 Hz), 116.0 (d, J_{C-F} = 21.6 Hz), 114.0, 22.1, 15.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₁₇H₁₆FN₂O₂S 331.0911; Found 331.0909.

4-(4-Chlorophenyl)-2-methyl-1-tosyl-1H-imidazole (3*f*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 94% yield (65 mg); mp 107-109 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.80 (d, J = 7.5 Hz, 2H), 7.66-7.65 (m, 3H), 7.36-7.32 (m, 4H), 2.56 (s, 3H), 2.43 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.6, 146.6, 139.9, 135.2, 133.8, 131.3, 130.8, 129.2, 127.8, 126.8, 114.5, 22.1, 15.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹/H¹6ClN²O²S 347.0616; Found 347.0612.

4-(4-Bromophenyl)-2-methyl-1-tosyl-1H-imidazole (3*g*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 93% yield (72 mg); mp 104-106 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.80 (d, J = 8.5 Hz, 2H), 7.67 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 2.56 (s, 3H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.7, 146.6, 139.9, 135.2, 132.2, 131.7, 130.8, 127.8, 127.1, 122.0, 114.6, 22.1, 15.6; HRMS (ESITOF) m/z: [M + H]+ Calcd for C¹γH¹6BrN²O²S 391.0110; Found 391.0109.

4-(4-(tert-Butyl)phenyl)-2-methyl-1-tosyl-1H-imidazole (3h). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 93% yield (68 mg); mp 69-71 °C; ${}^{1}H$ NMR (500 MHz, CDCl₃) δ 7.79 (d, J = 7.0 Hz, 2H), 7.69-7.64 (m, 3H), 7.39 (d, J = 7.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 2.57 (s, 3H), 2.42 (s, 3H), 1.32 (s, 9H); ${}^{13}C$ NMR (125 MHz, CDCl₃) δ 151.3, 146.4, 146.4, 141.0, 135.5, 130.7, 129.9, 127.7, 126.0, 125.3, 114.0, 35.0, 31.7, 22.1, 15.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₁H₂₅N₂O₂S 369.1631; Found 369.1634.

2-Methyl-1-tosyl-4-(4-(trifluoromethyl)phenyl)-1H-imidazole (3i). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 75% yield (57

C

mg); mp 76-78 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.84-7.82 (m, 4H), 7.76 (s, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 2.58 (s, 3H), 2.45 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.8, 139.5, 136.2, 135.1, 130.9, 129.9 (q, J_{C-F} = 32.5 Hz), 128.5, 127.9, 126.6, 126.1(q, J_{C-F} = 3.8 Hz), 124.6(q, J_{C-F} = 270.0 Hz), 115.6, 22.1, 15.5.; HRMS (ESI-TOF) m/z: [M + H] + Calcd for C₁₈H₁₆F₃N₂O₂S 381.0879; Found 381.0878.

2-Methyl-4-(4'-propyl-[1,1'-biphenyl]-4-yl)-1-tosyl-1H-imidazole (3j). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 80% yield (69 mg); mp 94-96 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.83-7.79 (m, 4H), 7.71(s, 1H), 7.61 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.5 Hz, 2H), 2.63 (t, J = 7.5 Hz, 2H), 2.59 (s, 3H), 1.72-1.64 (m, 2H), 0.98 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.5, 146.5, 142.4, 140.9, 140.7, 138.4, 135.4, 131.4, 130.8, 129.3, 127.8, 127.6, 127.1, 125.9, 114.3, 38.1, 25.0, 22.1, 15.6, 14.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂6H₂7N₂O₂S 431.1788; Found 431.1781.

2-Methyl-4-(m-tolyl)-1-tosyl-1H-imidazole (3k). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 95% yield (62 mg); mp 107-109 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.80 (d, J = 8.5 Hz, 2H), 7.67 (s, 1H), 7.58 (s, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.26 (t, J = 7.5 Hz, 1H), 7.09 (d, J = 7.5 Hz, 1H), 2.57 (s, 3H), 2.43 (s, 3H), 2.37 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.5, 146.4, 141.0, 138.8, 135.4, 132.5, 130.8, 129.0, 127.8, 126.2, 122.6, 114.3, 22.1, 21.8, 15.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹8H¹9N²O²S 327.1162; Found 327.1163.

4-(3-Chlorophenyl)-2-methyl-1-tosyl-1H-imidazole (3*l*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 85% yield (59 mg); mp 83-85 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, J = 8.0 Hz, 2H), 7.73 (s, 1H), 7.68 (s, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.29 (t, J = 8.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 2.56 (s, 3H), 2.44 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.7, 139.7, 135.1, 134.6, 130.8, 130.3, 128.1, 127.8, 125.7, 123.6, 115.0, 22.1, 15.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹7H¹6ClN²O₂S 347.0616; Found 347.0625.

4-(3-Bromophenyl)-2-methyl-1-tosyl-1H-imidazole (3m). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 82% yield (64 mg); mp 79-81 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.89 (s, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.67 (s, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.39-7.35 (m, 3H), 7.22 (t, J = 8.0 Hz, 1H), 2.56 (s, 3H), 2.43 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.7, 146.6, 139.5, 135.2, 134.8, 131.0, 130.8, 130.6, 128.6, 127.8, 124.1, 123.3, 115.0, 22.1, 15.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹γH¹6BrN²O²S 391.0110; Found 391.0119.

4-(2-Fluorophenyl)-2-methyl-1-tosyl-1H-imidazole (3n). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 79% yield (52 mg); mp 57-59 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.03 (t, J = 7.5 Hz, 1H), 7.85 (d, J = 4.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.23 (t, J = 7.0 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 7.10 (t, J = 10 Hz, 1H), 2.58 (s, 3H), 2.43 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 160.2 (d, J_{C-F} = 247.9 Hz), 146.5, 145.9, 135.4, 134.5, 130.8, 129.1 (d, J_{C-F} = 8.5 Hz), 128.2 (d, J_{C-F} = 3.6 Hz), 127.8, 124.7 (d, J_{C-F} = 3.6 Hz), 120.6 (d, J_{C-F} = 12.5 Hz), 118.4 (d, J_{C-F} = 15.4 Hz), 116.0 (d, J_{C-F} = 21.5 Hz), 22.1, 15.5; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C¹_TH¹₁₆FN₂O₂S 331.0911; Found 331.0914.

1-((4-Fluorophenyl)sulfonyl)-2-methyl-4-phenyl-1H-imidazole (3**o**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 91% yield (57 mg); mp 107-109 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.97-7.94 (m, 2H), 7.73 (d, J = 7.5 Hz, 2H), 7.67 (s, 1H), 7.38 (t, J = 8.0 Hz, 2H), 7.29 (t, J = 7.5 Hz, 1H), 7.24 (t, J = 8.0 Hz, 2H), 2.58 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.6 (d, J_{C-F} = 257.5 Hz), 146.4, 141.3, 134.4 (d, J_{C-F} = 2.8 Hz), 132.5, 130.7 (d, J_{C-F} = 9.8 Hz), 129.1, 128.4, 125.6, 117.7 (d, J_{C-F} = 22.9 Hz), 114.2, 15.7; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C¹₁₆H¹₁₄FN₂O₂S 317.0755; Found 317.0760.

1-((4-Bromophenyl)sulfonyl)-2-methyl-4-phenyl-1H-imidazole (3p). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 76% yield (57 mg); mp 97-99 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.78 (d, J = 9.0 Hz, 2H), 7.72 (t, J = 9.0 Hz, 4H), 7.65 (s, 1H), 7.38 (d, J = 7.5 Hz, 2H), 7.29 (d, J = 7.5 Hz, 1H), 2.58 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.5, 141.4, 137.3, 133.6, 132.4, 130.6, 129.1, 129.1, 128.4, 125.6, 114.2, 15.7; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹₅H¹₄BrN₂O₂S 376.9954; Found 376.9952.

2-Ethyl-4-phenyl-1-tosyl-1H-imidazole (3*q*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 56% yield (37 mg); mp 49-51 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.79 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 7.0 Hz, 2H), 7.67 (s, 1H), 7.39-7.34 (m, 4H), 7.28 (d, J = 7.5 Hz, 1H), 2.90 (q, J = 7.5 Hz, 2H), 2.43 (s, 3H), 1.32 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 151.4, 146.4, 140.9, 135.7, 132.9, 130.7, 129.0, 128.1, 127.7, 125.6, 114.3, 22.4, 22.1, 12.5; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C¹8H¹9N²2O²S 327.1162; Found 327.1163.

4-Phenyl-2-propyl-1-tosyl-1H-imidazole (3r). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a colorless oil in 45% yield (31 mg); ¹H NMR (500 MHz, CDCl₃) δ 7.79 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 7.0 Hz, 2H), 7.66 (s, 1H), 7.38-7.33 (m, 4H), 7.27 (t, J = 7.5 Hz, 1H), 2.85 (t, J = 7.5 Hz, 2H), 2.43 (s, 3H), 1.81-1.74 (m, 2H), 0.98 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 150.4, 146.4, 141.0, 135.8, 132.9, 130.7, 129.0, 128.1, 127.6, 125.6, 114.3, 30.8, 22.1, 21.9, 14.3; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₉H₂₁N₂O₂S 341.1318; Found 341.1312.

2-Butyl-4-phenyl-1-tosyl-1H-imidazole (3s). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a colorless oil in 44% yield (31 mg); 1 H NMR (500 MHz, CDCl₃) δ 7.79 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 7.5 Hz, 2H), 7.67 (s, 1H), 7.38-7.33 (m, 4H), 7.28 (d, J = 7.5 Hz, 1H), 2.87 (t, J = 8 Hz, 2H), 2.43 (s, 3H), 1.72-1.69 (m, 2H), 1.42-1.37 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H); 13 C NMR (125 MHz, CDCl₃) δ 150.5, 146.4, 140.9, 135.7, 132.9, 130.7, 129.1, 128.2, 127.7, 125.6, 114.3, 30.5, 28.6, 22.9, 22.1, 14.2; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₀H₂₃N₂O₂S 355.1475; Found 355.1482.

(2,5-Diphenyl-1H-pyrrol-3-yl)(phenyl)methanone (5a). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 91% yield (59 mg); mp 81-83 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.98 (s, 1H), 7.80 (d, J = 7.0 Hz, 2H), 7.54 (d, J = 7.5 Hz, 2H), 7.45-7.42 (m, 3H), 7.39 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.29-7.24 (m, 4H), 6.84 (d, J = 3.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 192.9, 139.8, 138.3, 132.3, 132.1, 131.8, 130.1, 129.5, 128.9, 128.8, 128.5, 128.3, 127.5, 124.5, 122.3, 110.9; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C23H18NO 324.1383; Found 324.1382.

Phenyl(2-*phenyl*-5-(*p*-tolyl)-1*H*-*pyrrol*-3-*y*l)*methanone* (*5b*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 91% yield (61 mg); mp 81-83 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.12 (s, 1H), 7.79 (d, *J* = 8.0 Hz, 2H), 7.47 – 7.38 (m, 5H), 7.31 (t, *J* = 7.7 Hz, 2H), 7.21 - 7.17 (m, 5H), 6.78 (s, 1H), 2.36 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 193.1, 139.8, 138.1, 137.3, 132.5, 132.2, 132.1, 130.1, 130.1, 129.1, 128.9, 128.7, 128.4, 128.3, 124.6, 122.2, 110.4, 21.6; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₄H₂₀NO 338.1539; Found 338.1545.

(5-(4-Ethylphenyl)-2-phenyl-1H-pyrrol-3-yl)(phenyl)methanone (5c). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 92% yield (64 mg); mp 71-73 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.92 (s, 1H), 7.80 (d, J = 7.0 Hz, 2H), 7.47-7.42 (m, 5H), 7.32 (t, J = 7.5 Hz, 2H), 7.26-7.22 (m, 5H), 6.81 (d, J = 3.0 Hz, 1H), 2.67 (q, J = 7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 193.0, 143.8, 139.8, 138.0, 132.5, 132.2, 132.1, 130.1, 129.3, 128.9, 128.7, 128.4, 128.3, 124.6, 122.2, 110.4, 29.0, 15.9; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂5H₂2NO 352.1693; Found 352.1689.

(5-(4-Methoxyphenyl)-2-phenyl-1H-pyrrol-3-yl)(phenyl)methanone (5d). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 92% yield (65 mg); mp 111-113 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.96 (s, 1H), 7.79 (d, J = 7.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 7.0 Hz, 3H), 7.31 (t, J = 7.5 Hz, 2H), 7.22 (d, J = 7.5 Hz, 3H), 6.92 (d, J = 8.5 Hz, 2H), 6.72 (d, J = 3.0 Hz, 1H), 3.82 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 193.1, 159.3, 139.9, 137.9, 132.4, 132.3, 132.1, 130.1, 128.9, 128.7, 128.3, 128.3, 126.0, 124.8, 122.2, 114.9, 109.8, 55.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂4H₂₀NO 354.1489; Found 354.1489.

(5-(4-Fluorophenyl)-2-phenyl-1H-pyrrol-3-yl)(phenyl) methanone (5e). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 85% yield (58 mg); mp 104-106 °C; 1 H NMR (500 MHz, CDCl $_3$) δ 8.93 (s, 1H), 7.78 (d, J = 7.0 Hz, 2H), 7.50 (dd, J = 9.0, 5.0 Hz, 2H), 7.45-7.41 (m, 3H), 7.31 (t, J = 7.5 Hz, 2H), 7.24-7.22 (m, 3H), 7.08 (t, J = 8.5 Hz, 2H), 6.76 (d, J = 7.5 Hz, 1H); 13 C NMR (125 MHz, CDCl $_3$) δ 192.9, 162.4 (d, J_{C-F} = 245.0 Hz), 139.7, 138.3, 132.2,

132.1, 131.5, 130.1, 128.8 (d, $J_{C-F} = 6.3 \text{ Hz}$), 128.6, 128.3, 128.2, 126.4, 126.3, 122.4, 116.5 (d, $J_{C-F} = 22.5 \text{ Hz}$), 110.7; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₃H₁₇FNO 342.1289; Found 342.1287.

(5-(4-Chlorophenyl)-2-phenyl-1H-pyrrol-3-yl)(phenyl)methanone (5f). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 84% yield (60 mg); mp 112-114 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.04 (s, 1H), 7.77 (d, J = 7.0Hz, 2H), 7.46 – 7.42 (m, 3H), 7.39 (dd, J = 6.5, 3.0 Hz, 2H), 7.35-7.30 (m, 4H), 7.23 – 7.19 (m, 3H), 6.79 (d, J = 3.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 192.9, 139.6, 138.6, 133.1, 132.2, 131.9, 131.3, 130.4, 130.1, 129.6, 128.9, 128.8, 128.6, 128.3, 125.8, 122.4, 111.2; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₃H₁γClNO 358.0993; Found 358.1002.

(5-(4-Bromophenyl)-2-phenyl-1H-pyrrol-3-yl)(phenyl)methanone (5 \mathbf{g}). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 84% yield (67 mg); mp 127-129 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.77 (s, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 7.46-7.43 (m, 3H), 7.40 (d, J = 8.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.29-7.27 (m, 3H), 6.85 (d, J = 7.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 193.0, 139.6, 138.7, 132.5, 132.3, 131.9, 131.3, 130.8, 130.1, 128.9, 128.7, 128.6, 128.3, 126.1, 122.4, 121.1, 111.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₃H₁₇BrNO 402.0488; Found 402.0489.

(5-(4-(tert-Butyl)phenyl)-2-phenyl-1H-pyrrol-3-yl)(phenyl)methanone (5h). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 93% yield (70 mg); mp 98-100 °C; ¹H NMR (500 MHz, CDCl³) δ 8.89 (s, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.49 – 7.40 (m, 7H), 7.32 (t, J = 8.0 Hz, 2H), 7.28 – 7.23 (m, 3H), 6.82 (s, 1H), 1.34 (s, 9H); ¹³C NMR (125 MHz, CDCl³) δ 192.9, 150.7, 139.8, 138.0, 132.4, 132.3, 132.1, 130.1, 129.1, 128.9, 128.8, 128.4, 128.3, 126.4, 124.3, 122.3, 110.5, 35.0, 31.7; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C27H26NO 380.2009; Found 380.2008.

Phenyl(2-*phenyl*-5-(4'-*propyl*-[1,1'-*biphenyl*]-4-*yl*)-1*H*-*pyrrol*-3-*yl*)*methanone* (*5i*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 85% yield (72 mg); mp 149-151 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.43 (s, 1H), 7.80 (d, J = 7.5 Hz, 2H), 7.59 (s, 4H), 7.52 (d, J = 8.0 Hz, 2H), 7.44 (t, J = 7.5 Hz, 1H), 7.41-7.36 (m, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 7.20 – 7.15 (m, 3H), 6.85 (d, J = 3.0 Hz, 1H), 2.64 (d, J = 8.0 Hz, 2H), 1.69 (m, 2H), 0.99 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 193.3, 142.5, 140.0, 139.8, 138.7, 138.2, 132.3, 132.2, 132.1, 130.5, 130.2, 129.4, 129.0, 128.7, 128.4, 128.3, 127.8, 127.1, 125.0, 122.3, 110.9, 38.1, 25.0, 14.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₃²H₂8NO 442.2165; Found 442.2170.

Phenyl(2-*phenyl*-5-(*m*-tolyl)-1H-*pyrrol*-3-yl)*methanone* (5*j*). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 86% yield (58 mg); mp 118-120 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.08 (s, 1H), 7.80 (d, J = 7.5 Hz, 2H), 7.43 (d, J = 6.0 Hz, 3H), 7.37-7.31 (m, 4H), 7.27 (d, J = 7.5 Hz, 1H), 7.22 (t, J = 6.0 Hz, 3H), 7.08 (d, J = 7.5 Hz, 1H), 6.82 (d, J = 2.5 Hz, 1H), 2.38 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 193.1, 139.8, 139.0, 138.4, 132.5, 132.2, 132.1, 131.8, 130.1, 129.3, 128.9, 128.7, 128.4, 128.3, 125.4, 122.2, 121.7, 110.8, 21.9; HRMS (ESITOF) m/z: [M + H]+ Calcd for C₂4H₂₀NO 338.1539; Found 338.1531.

(5-(3-Chlorophenyl)-2-phenyl-1*H*-pyrrol-3-yl)(phenyl)methanone (**5k**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 85% yield (60 mg); mp 83-85 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.19 (s, 1H), 7.78 (d, J = 7.5 Hz, 2H), 7.51 (s, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.41-7.38 (m, 3H), 7.34-7.27 (m, 3H), 7.23 – 7.18 (m, 4H), 6.80 (d, J = 2.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 193.0, 139.6, 138.9, 135.4, 133.6, 132.3, 131.8, 130.9, 130.6, 130.1, 128.9, 128.7, 128.6, 128.4, 127.3, 124.6, 122.6, 122.3, 111.7; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂³H¹²ClNO 358.0993; Found 358.0992.

(5-(3-Bromophenyl)-2-phenyl-1*H*-pyrrol-3-yl)(phenyl)methanone (**5l**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 87% yield (69 mg); mp 99-101 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.10 (s, 1H), 7.78 (d, J = 7.0 Hz, 2H), 7.67 (s, 1H), 7.46 – 7.40 (m, 4H), 7.37 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 8.0 Hz, 2H), 7.25 – 7.21 (m, 4H), 6.81 (d, J = 2.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 192.9, 139.6, 138.9, 133.9, 132.3, 131.8, 130.9, 130.7, 130.2, 130.1, 128.9, 128.8, 128.7, 128.4, 127.4, 123.6, 123.1, 122.4, 111.7; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂³H¹¬²BrNO 402.0488; Found 402.0489.

(5-(2-Fluorophenyl)-2-phenyl-1*H*-pyrrol-3-yl)(phenyl)methanone (**5m**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 79% yield (54 mg); mp 77-79 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.39 (s, 1H), 7.81 (d, J = 7.0 Hz, 2H), 7.64 (t, J = 8.0 Hz, 1H), 7.48 - 7.44 (m, 3H), 7.34 (t, J = 8.0 Hz, 2H), 7.29 - 7.26 (m, 3H), 7.23 – 7.13 (m, 3H), 6.98 (d, J = 3.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 192.8, 159.2 (d, J_{C-F} = 124.1 Hz), 139.7, 138.3, 132.2, 132.0, 130.1, 128.8, 128.6, 128.57 (d, J_{C-F} = 8.5 Hz), 128.4, 127.3 (d, J_{C-F} = 4.0 Hz), 127.1, 125.3 (d, J_{C-F} = 3.0 Hz), 121.7, 119.4, 119.3, 116.8 (d, J_{C-F} = 23.8 Hz), 112.7; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂³H¹¬FNO 342.1289; Found 342.1281.

(4-Chlorophenyl)(2-(4-chlorophenyl)-5-phenyl-1*H*-pyrrol-3-yl) methanone (**5n**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 75% yield (58 mg); mp 94-96 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.75 (s, 1H), 7.77 (d, J = 9.0 Hz, 2H), 7.53 (d, J = 7.0 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.42 (t, J = 8.0 Hz, 2H), 7.34 (m, 4H), 6.80 (d, J = 2.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 191.2, 138.7, 138.0, 136.8, 134.8, 132.7, 131.4, 130.5, 130.0, 129.6, 129.2, 128.8, 127.9, 124.6, 122.3, 110.8; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₃H¹₀Cl₂NO 392.0603; Found 392.0612.

(2,5-Diphenyl-1*H*-pyrrol-3-yl) (naphthalen-2-yl) methanone (**50**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 92% yield (68 mg); mp 107-109 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.81 (s, 1H), 8.34 (s, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.83 (t, J = 8.0 Hz, 3H), 7.60 – 7.52 (m, 5H), 7.49 (d, J = 7.0 Hz, 1H), 7.42 (t, J = 8.0 Hz, 2H), 7.31 – 7.26 (m, 3H), 7.22 (d, J = 7.5 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 192.7, 138.1, 137.0, 135.4, 132.7, 132.3, 132.2, 131.8, 131.7, 129.7, 129.5, 128.9, 128.8, 128.6, 128.2, 128.2, 128.1, 127.6, 126.8, 126.1, 124.5, 122.6, 111.0; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂¬H₂₀NO 374.1539; Found 374.1537.

(2,5-Diphenyl-1*H*-pyrrol-3-yl) (thiophen-2-yl) methanone (**5p**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 90% yield (59 mg); mp 86-88 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.77 (s, 1H), 7.66 (d, J = 3.5 Hz, 1H), 7.60 – 7.54 (m, 5H), 7.42 (t, J = 8.0 Hz, 2H), 7.36 (t, J = 7.0 Hz, 2H), 7.33 – 7.28 (m, 2H), 7.04 (dd, J = 5.0, 4.0 Hz, 1H), 6.99 (d, J = 3.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 184.1, 145.9, 137.4, 134.1, 133.2, 132.4, 132.1, 131.8, 129.5, 129.0, 128.7, 128.6, 128.0, 127.6, 124.6, 122.3, 110.2; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂¹H¹6NOS 330.0947; Found 330.0955.

(2-Isopropyl-5-phenyl-1*H*-pyrrol-3-yl) (phenyl)methanone (**5q**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 86% yield (50 mg); mp 85-87 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.79 (s, 1H), 7.84 (d, J = 7.0 Hz, 2H), 7.53 (t, J = 7.0 Hz, 1H), 7.48 – 7.44 (m, 4H), 7.36 (t, J = 7.5 Hz, 2H), 7.23 (t, J = 7.5 Hz, 1H), 6.64 (d, J = 3.0 Hz, 1H), 3.87 (m, 1H), 1.37 (d, J = 7.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 192.8, 147.8, 141.1, 132.2, 131.6, 129.8, 129.5, 129.4, 128.5, 127.2, 124.3, 120.2, 110.1, 26.8, 22.4; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂0H₂0NO 290.1539; Found 290.1530.

Phenyl(5-phenyl-2-propyl-1*H*-pyrrol-3-yl) methanone (**5r**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 42% yield (24 mg); mp 74-76 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.68 (s, 1H), 7.87 – 7.82 (m, 2H), 7.53 (t, J = 7.5 Hz, 1H), 7.49 – 7.44 (m, 4H), 7.39 – 7.34 (m, 2H), 7.23 (t, J = 7.5 Hz, 1H), 6.66 (d, J = 3.0 Hz, 1H), 3.02 (t, J = 7.5 Hz, 2H), 1.76 (m, 2H), 1.60 (s, 3H), 1.01 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 192.7, 142.4, 141.0, 132.1, 131.6, 130.0, 129.5, 129.4, 128.5, 127.1, 124.2, 121.2, 109.8, 30.1, 23.1, 14.4; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₀H₂₀NO 290.1539; Found 290.1542.

(2-Butyl-5-phenyl-1*H*-pyrrol-3-yl) (phenyl)methanone (**5s**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 49% yield (30 mg); mp 74-76 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.24 (s, 1H), 7.85 (d, J = 8.0 Hz, 2H), 7.55 - 7.45 (m, 5H), 7.34 (t, J = 7.0 Hz, 2H), 7.21 (t, J = 7.5 Hz, 1H), 6.67 (s, 1H), 3.01 (t, J = 7.5 Hz, 2H), 1.7-1.64 (m, 2H), 1.39 - 1.32 (m, 2H), 0.89 (t, J = 7.0 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 192.7, 142.7, 140.7, 131.8, 131.3, 129.8, 129.1, 129.0, 128.1, 126.6, 123.9, 120.6, 109.4, 31.7, 27.5, 22.6, 14.0, 13.9; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₁H₂₂NO 304.1696; Found 304.1702.

(1,2-Dimethyl-5-phenyl-1*H*-pyrrol-3-yl) (phenyl)methanone (**7a**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 72% yield (40 mg); mp 96-98 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.64 (d, J = 7.0 Hz, 2H), 7.26 (t, J = 7.5Hz, 1H), 7.14 (t, J = 7.5 Hz, 2H), 7.04 (q, J = 8.0 Hz, 4H), 6.98 (d, J = 6.5 Hz, 1H), 6.64 (s, 1H), 3.62 (s, 3H), 2.38 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 194.4, 140.0, 135.8, 135.6, 131.9, 130.2, 128.8, 128.2, 128.0, 126.2, 125.9, 120.2, 120.1, 34.2, 11.7; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₁₉H₁₈NO 276.1383; Found 276.1388.

1-(2-Methyl-5-phenyl-1-(p-tolyl)-1H-pyrrol-3-yl) ethan-1-one (**7b**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a yellow solid in 85% yield (49 mg); mp 66-68 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.38 (d, J = 4.0 Hz, 4H), 7.32 – 7.27 (m, 3H), 7.21 (d, J = 8.5 Hz, 2H), 6.64 (s, 1H), 2.42 (s, 3H), 2.39 (s, 3H), 2.07 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 198.1, 138.5, 136.6, 136.5, 135.8, 130.3, 129.7, 128.7, 127.2, 126.6, 126.4, 122.8, 121.1, 31.5, 21.5, 13.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₀H₂₀NO 290.1539; Found 290.1538.

2-Methyl-4-phenyl-1*H*-imidazole (8). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 3) to afford a white solid in 96% yield (30 mg); mp 57-59 °C; 1 H NMR (500 MHz, CDCl₃) δ 7.67 (d, J = 7.0 Hz, 2H), 7.37 (s, 1H), 7.30 (t, J = 7.5Hz, 2H), 7.13 (t, J = 7.5 Hz, 1H), 2.29 (s, 3H); 13 C NMR (125 MHz, DMSO- $d\epsilon$) δ 145.7, 138.2, 133.2, 129.1, 127.2, 125.1, 115.6, 14.2; HRMS (ESI-TOF) m/z: [M + H] $^{+}$ Calcd for C₁₀H₁₁N₂ 159.0917; Found 159.091.

(*E*)-(2,5-Diphenyl-1*H*-pyrrol-3-yl) (phenyl)methanone oxime (9). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a white solid in 94% yield (63 mg); mp 95-97 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 11.44 (s, 1H), 11.19 (s, 1H), 7.79 (d, J = 7.5 Hz, 2H), 7.49 (d, J = 7.5 Hz, 4H), 7.37 (t, J = 8.0 Hz, 2H), 7.26-7.23 (m, 5H), 7.19 (t, J = 7.5 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 6.52 (d, J = 3.0 Hz, 1H); ¹³C NMR (125 MHz, DMSO- d_6) δ 153.7, 137.7, 133.2, 132.8, 131.6, 129.6, 129.5, 129.1, 129.0, 128.8, 127.4, 127.2, 127.0, 126.5, 124.8, 115.1, 109.2; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₃H₁₉N₂O 339.1492; Found 339.1496.

(1-Methyl-2,5-diphenyl-1*H*-pyrrol-3-yl) (phenyl)methanone (**10**). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1: 8) to afford a colorless oil in 98% yield (66 mg); ¹H NMR (500 MHz, CDCl₃) δ 7.76 (d, J = 7.0 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.45 (t, J = 8.0 Hz, 2H), 7.40 – 7.35 (m, 5H), 7.34 (s, 1H), 7.32 – 7.27 (m, 3H), 6.67 (s, 1H), 3.49 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 192.3, 140.8, 140.1, 135.7, 132.9, 132.3, 131.6, 131.2, 129.8, 129.4, 129.0, 128.6, 128.5, 128.1, 128.1, 122.3, 112.3, 34.3; HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C₂₄H₂₀NO 338.1539; Found 338.1544.

References

- 1. Weinreb, S. M. Some recent advances in the synthesis of polycyclic imidazole-containing marine natural products. *Nat. Prod. Rep.* **2007**, *24*, 931-948.
- 2. Robertson, J.; Stevens, K. Pyrrolizidine alkaloids. Nat. Prod. Rep. 2014, 31, 1721-1788.
- 3. Muñoz, J.; Ko¨ck, M. Hybrid pyrrole-imidazole alkaloids from the sponge agelas sceptrum. *J. Nat. Prod.* **2016**, **79**, 434–437.
- 4. Clive, D. L. J.; Cheng, P. The marinopyrroles. *Tetrahedron* **2013**, *69*, 5067-5078.
- 5. Shabalin, D. A.; Camp, J. E. Recent advances in the synthesis of imidazoles. *Org. Biomol. Chem.* **2020**, *18*, 3950-3964.
- 6. Vessally, E.; Soleimani-Amiri, S.; Hosseinian, A.; Edjlali, L.; Bekhradnia, A. New protocols to access imidazoles and their ring fused analogues: synthesis from *N*-propargylamines. *RSC Adv.* **2017**, *7*, 7079-7091.
- 7. Khajuria, R.; Dham, S.; Kapoor, K. K. Active methylenes in the synthesis of a pyrrole motif: an imperative structural unit of pharmaceuticals, natural products and optoelectronic materials. *RSC Adv.* **2016**, *6*, 37039–37066.
- 8. Borah, B.; Dwivedi, K. D.; Chowhan, L. R. Recent approaches in the organocatalytic synthesis of pyrroles. *RSC Adv.* **2021**, *11*, 13585-13601.
- 9. Preeti; Singh, K. N. Multicomponent reactions: a sustainable tool to 1,2- and 1,3-azoles. *Org. Biomol. Chem.* **2018**, *16*, 9084-9116.
- 10. Estévez, V.; Villacampa, M.; Menéndez, J. C. Recent advances in the synthesis of pyrroles by multicomponent reactions. *Chem. Soc. Rev.* **2014**, 43, 4633-4657.
- 11. Shi, S.; Xu, K.; Jiang, C.; Ding, Z. ZnCl₂-Catalyzed [3+2] Cycloaddition of Benzimidates and 2*H*-Azirines for the Synthesis of Imidazoles. *J. Org. Chem.* **2018**, *83*, 14791-14796.
- 12. Xie, J.; Huang, Y.; Song, H.; Liu, Y.; Wang, Q. Copper-Catalyzed Aerobic Oxidative [2+3] Cyclization/Aromatization Cascade Reaction: Atom-Economical Access to Tetrasubstituted 4,5-Biscarbonyl Imidazoles. Org. Lett. **2017**, *19*, 6056-6059.

- 13. Liao, J.-Y.; Shao, P.-L.; Zhao, Y. Catalytic Divergent Synthesis of 3H or 1H Pyrroles by [3 + 2] Cyclization of Allenoates with Activated Isocyanides. *J. Am. Chem. Soc.* **2015**, *137*, 628-631.
- 14. Vannada, J.; Sulthan, M.; Arun, D.; Dada, R.; Yaragorla, S. Regiodivergent Synthesis of Penta-Substituted Pyrroles through a Cascade [3 + 2] Cyclization of C-Acylimines with Activated Alkynes and Aromatic Nucleophiles. *J. Org. Chem.* **2020**, *85*, 6697-6708.
- 15. Dai, L.; Yu, S.; Lv, N.; Ye, X.; Shao, Y.; Chen, Z.; Chen, J. Synthesis of Imidazoles and Oxazoles via a Palladium-Catalyzed Decarboxylative Addition/Cyclization Reaction Sequence of Aromatic Carboxylic Acids with Functionalized Aliphatic Nitriles. *Org. Lett.* **2021**, *23*, 5664-5668.
- 16. Kurita, S.; Kiyota, S.; Komine, N.; Hirano, M. Ru(0)-Catalyzed Synthesis of Conjugated Iminotrienes and Subsequent Intramolecular Cyclization Giving Polysubstituted Pyrroles. *Org. Lett.* **2022**, *24*, 2973-2977.
- 17. Li, S.; Li, Z.; Yuan, Y.; Peng, D.; Li, Y.; Zhang, L.; Wu, Y. Au(I)-Catalyzed Intramolecular Hydroamination of the Fluorinated N'-Aryl-N-Propargyl Amidines: Mild Conditions for the Synthesis of 2-Fluoroalkyl Imidazole Derivatives. *Org. Lett.* **2012**, *14*, 1130-1133.
- 18. Li, W.; Shi, R.; Chen, S.; Zhang, X.; Peng, W.; Chen, S.; Li, J.; Xu, X.-M.; Zhu, Y.-P.; Wang, X. Synthesis of Diverse Pentasubstituted Pyrroles by a Gold(I)-Catalyzed Cascade Rearrangement-Cyclization of Tertiary Enamide. *J. Org. Chem.* **2022**, *87*, 3014-3024.
- 19. Akter, M.; Rupa, K.; Anbarasan, P. 1,2,3-Triazole and Its Analogues: New Surrogates for Diazo Compounds. *Chem. Rev.* 2022, 122, 13108–13205.
- 20. Huang, J.; Zhou, H.; Chen, Z. Advances on the Metallocarbene Formation Reactions Based on Triazole Derivatives. *Chin. J. Org. Chem.* **2016**, *36*, 1555-1563.
- 21. Davies, H. M. L.; Alford, J. S. Reactions of metallocarbenes derived from *N*-sulfonyl-1,2,3-triazoles. *Chem. Soc. Rev.* **2014**, 43, 5151-5162.
- 22. Jiang, Y.; Sun, R.; Tang, X.-Y.; Shi, M. Recent Advancesin the Synthesis of Heterocycles and RelatedSubstances Based on α-Imino Rhodium Carbene ComplexesDerived from *N*-Sulfonyl-1,2,3-triazoles. *Chem. Eur. J.* **2016**, 22, 17910–17924.
- 23. Chuprakov, S.; Kwok, S. W.; Zhang, L.; Lercher, L.; Fokin, V. V. Rhodium-Catalyzed Enantioselective Cyclopropanation of Olefins with *N*-Sulfonyl 1,2,3-Triazoles. *J. Am. Chem. Soc.* **2009**, *131*, 18034–18035.
- 24. Miura, T.; Nakamuro, T.; Ishihara, Y.; Nagata, Y.; Murakami, M. Chiral Macrocycles Having C3 Symmetry Resulting from Orientation of Thiophene Rings. *Angew. Chem., Int. Ed.* **2020**, *59*, 20475–20479.
- 25. Chuprakov, S.; Worrell, B. T.; Selander, N.; Sit, R. K.; Fokin, V. V. Stereoselective 1,3-Insertions of Rhodium(II) Azavinyl Carbenes. *J. Am. Chem. Soc.* **2014**, *136*, 195–202.
- 26. He, X.; Wu, Y.; Zhou, T.; Zuo, Y.; Xie, M.; Li, R.; Duan, J.; Shang, Y. Rh-Catalyzed C-N Coupling of N-Sulfonyl-1,2,3-Trizales with Secondary Amines for Regioselective Synthesis of Phenylvinyl-1,2-Diamines. *Synth. Commun.* **2020**, *50*, 2685–2697.
- 27. Chen, Y.; Liu, Y.; Li, Z.; Dong, S.; Liu, X.; Feng, X. Tandem Insertion-[1,3]-Rearrangement: Highly Enantioselective Construction of *α*-Aminoketones. *Angew. Chem., Int. Ed.* **2020**, *59*, 8052–8056.
- 28. Miura, T.; Nakamuro, T.; Miyakawa, S.; Murakami, M. A Syn-Selective Aza-Aldol Reaction of Boron Aza-Enolates Generated fromNSulfonyl-1,2,3-Triazoles and 9-BBN-H. *Angew. Chem., Int. Ed.* **2016**, *55*, 8732–8735.
- 29. He, J.; Shi, Y.; Cheng, W.; Man, Z.; Yang, D.; Li, C.-Y. Rhodium-Catalyzed Synthesis of 4-Bromo-1,2-Dihydroisoquinolines: Access to Bromonium Ylides by the Intramolecular Reaction of a Benzyl Bromide and an α -Imino Carbene. Angew. Chem., Int. Ed. 2016, 55, 4557–4561.
- 30. Reddy, A. C. S.; Ramachandran, K.; Reddy, P. M.; Anbarasan, P. Rhodium-Catalyzed Sommelet Hauser Type Rearrangement of α -Diazoimines: Synthesis of Functionalized Enamides. *Chem. Commun.* **2020**, *56*, 5649–5652.
- 31. Yu, Y.; Zhu, L.; Liao, Y.; Mao, Z.; Huang, X. Rhodium(II)-Catalysed Skeletal Rearrangement of Ether Tethered N-Sulfonyl 1,2,3-Triazoles: A Rapid Approach to 2-Aminoindanone and Dihydroisoquinoline Derivatives. *Adv. Synth. Catal.* **2016**, *358*, 1059–1064.
- 32. Zhang, W.-B.; Xiu, S.-D.; Li, C.-Y. Rhodium-catalyzed synthesis of multi-substituted furans from N-sulfonyl-1,2,3-triazoles bearing a tethered carbonyl group. *Org. Chem. Front.* **2015**, 2, 47-50.
- 33. Shi, Y.; Yu, X.; Li, C.-Y. Rhodium-Catalyzed Synthesis of 2,5-Epoxybenzo[f][1,4]Oxazepines by Tandem Reaction of 1-Sulfonyl-1,2,3-Triazoles and Salicylaldehydes. *Eur. J. Org. Chem.* **2015**, 2015, 6429–6433.
- 34. Yadagiri, D.; Reddy, A. C. S.; Anbarasan, P. Rhodium Catalyzed Diastereoselective Synthesis of 2,2,3,3-Tetrasubstituted Indolines from N-Sulfonyl-1,2,3-Triazoles and Ortho-Vinylanilines. *Chem. Sci.* **2016**, 7, 5934–5938.
- 35. Miura, T.; Fujimoto, Y.; Funakoshi, Y.; Murakami, M. A Reaction of Triazoles with Thioesters to Produce β-Sulfanyl Enamides by Insertion of an Enamine Moiety into the Sulfur-Carbonyl Bond. *Angew. Chem., Int. Ed.* **2015**, *54*, 9967–9970.
- 36. He, X.; Li, R.; Choy, P. Y.; Duan, J.; Yin, Z.; Xu, K.; Tang, Q.; Zhong, R.-L.; Shang, Y.; Kwong, F. Y. An expeditious FeCl3-catalyzed cascade 1,4-conjugate addition/annulation/1,5-H shift sequence for modular access of all-pyrano-moiety-substituted chromenes. *Chem. Sci.* **2022**, *13*, 13617-13622.

- 37. Zhou, T.; He, X.; Zuo, Y.; Wu, Y.; Hu, W.; Zhang, S.; Duan, J.; Shang, Y. Rh-catalyzed formal [3+2] cyclization for synthesis of 5-aryl-2-(quinolin-2-yl)oxazoles and its applications in metal ions probes. *Chin. J. Chem.* **2021**, *39*, 621-626.
- 38. He, X.; Xu, K.; Liu, Y.; Wang, D.; Tang, Q.; Hui, W.; Chen, H.; Shang, Y. Radical-Induced Cascade Annulation/Hydrocarbonylation for Construction of 2-Aryl-4H-chromen-4-ones. *Molecules* **2022**, 27, 7412.
- 39. Fang, T.; Zhang, S.; Ye, Q.; Kong, S.; Yang, T.; Tang, K.; He, X.; Shang, Y. Rh-catalyzed Cascade C-H Activation/Annulation of *N*-Hydroxybenzamides and Propargylic Acetates for Modular Access to Isoquinolones. *Molecules* **2022**, *27*, 8553.
- 40. Jeon, H. J.; Jung, D. J.; Kim, J. H.; Kim, Y.; Bouffard, J.; Lee, S. From Triazoles to Imidazolines through the Sequential N–H Insertion of α -Imino Rhodium–Carbenes into β -Enamino Esters/Enamine–Imine Tautomerization/Conjugate Addition Cascade. *J. Org. Chem.* **2014**, *79*, 9865–9871.
- 41. Lei, X.; Li, L.; He, Y.-P.; Tang, Y. Rhodium(II)-Catalyzed Formal [3 + 2] Cycloaddition of N-Sulfonyl-1,2,3-Triazoles with Isoxazoles: Entry to Polysubstituted 3-Aminopyrroles. *Org. Lett.* **2015**, *17*, 5224–5227.
- 42. Rostovskii, N. V.; Ruvinskaya, J. O.; Novikov, M. S.; Khlebnikov, A. F.; Smetanin, I. A.; Agafonova, A. V. Switchable Synthesis of Pyrroles and Pyrazines *via* Rh(II)-Catalyzed Reaction of 1,2,3-Triazoles with Isoxazoles: Experimental and DFT Evidence for the 1,4-Diazahexatriene Intermediate. *J. Org. Chem.* **2017**, 82, 256–268.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.